Skip to main content
. Author manuscript; available in PMC: 2009 Sep 30.
Published in final edited form as: Neuropsychopharmacology. 2008 Jul 9;34(3):624–633. doi: 10.1038/npp.2008.104

Figure 2.

Figure 2

[11C]flumazenil-binding potential (BPND) derived through SRTM in eight healthy control individuals at baseline and 30 min after receiving tiagabine 16 mg p.o. Notably, one individual displayed decreased [11C]flumazenil binding across all regions.